Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
HROWthis companyHarrow Health, Inc.	$26.74	-350×	34.35×	6.61×	47×	-1507.5%	75.1%	14.2%	-1.9%	-9.8%	12.7%	2.4%	4.8×	4.25×	1.6×	2.2×	0.0%	4	1.85	1	C-
EYPTEyePoint Pharmaceuticals, Inc.	$0.35	-5.76×	4.37×	42.66×	-5.49×	-1218.8%	93.4%	-776.0%	-739.4%	-75.8%	-74.0%	-18.2%	0.07×	0.34×	0×	8.88×	0.0%	2	-11.09	1	C-
KODKodiak Sciences Inc.	$105.57	-6.47×	9.45×	0×	-7.06×	-99.2%	0.0%	0.0%	0.0%	-146.1%	-73.7%	-9.2%	1.01×	0.25×	0×	4.72×	0.0%	1	7.23	1	D+
OCULOcular Therapeutix, Inc.	$6.63	-8.55×	3.47×	43.86×	-6.47×	-101.4%	87.3%	-521.0%	-513.2%	-40.6%	-35.5%	-9.5%	0.12×	2.63×	-22.82×	15.39×	0.0%	2	2.82	1	C-
OTLKOutlook Therapeutics, Inc.	$0.45	-0.59×	-0.84×	19.1×	-0.77×	82.8%	46.5%	-4744.3%	-4416.2%	193.9%	-2357.6%	-191.9%	-0.94×	-0.35×	-236.86×	0.38×	0.0%	3	-41.23	2	C
TARSTarsus Pharmaceuticals, Inc.	$68.34	-51.5×	9.96×	7.58×	-62.14×	-639.1%	93.2%	-15.7%	-14.7%	-19.3%	-16.6%	-0.7%	0.27×	1.68×	-7.94×	3.85×	0.0%	3	8.3	1	D+
Peer median	—	-6.47×	4.37×	19.1×	-6.47×	-101.4%	87.3%	-521.0%	-513.2%	-40.6%	-73.7%	-9.5%	0.12×	0.34×	-7.94×	4.72×	0.0%	2	2.82	1	—